Core A, the Administrative Core, will continue to provide organizational support for the leadership of the SPORE, facilitate communication among the component activities of the SPORE, serve as the home for pancreatic cancer SPORE advocate activities, and provide an organizational portal for collaborations outside the SPORE. Core A's functions are to: 1) Provide leadership and coordination between the Research Projects and Cores of the SPORE;2) Assure ongoing integration and participation of the Pancreatic Cancer SPORE in the activities of Mayo Clinic Cancer Center;3) Organize monthly meetings of the SPORE investigators;4) Organize yearly research retreats and meetings of the External Advisory Committee;5) Organize meetings of the SPORE Scientific Advisory Committee as needed;6) Organize monthly meetings of the SPORE Steering Committee;7) Provide administrative support to the Developmental Research Program;8) Provide administrative support to the Career Development Program;9) Facilitate investigator trips to the annual SPORE meetings in the mid-Atlantic region;10) Facilitate activities of the pancreatic cancer SPORE advocates;11) Prepare the yearly non-competing SPORE application;12) Serve as the administrative liaison between the Mayo Clinic SPORE and the NCI SPORE Program, other SPOREs, and collateral resources, such as PACGENE, PANC4, PanCAN, the Phase II Consortium, and the North Central Cancer Treatment Group;13) Maintain the Mayo Pancreatic Cancer SPORE websites that will be useful to investigators inside and outside the SPORE, as well as patients;14) Coordinate information and communication about SPORE-related research developments to and among the Mayo Clinic SPORE investigators, to the scientific community at large, and to the public. The Core leader, Dr. Petersen, will continue to direct Core A in close consultation with the Steering Committee so that maximum potential for translational objectives can continue to be achieved.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA102701-09
Application #
8316349
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
9
Fiscal Year
2011
Total Cost
$160,773
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Chaffee, Kari G; Oberg, Ann L; McWilliams, Robert R et al. (2018) Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Genet Med 20:119-127
Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:
McWilliams, Robert R; Wieben, Eric D; Chaffee, Kari G et al. (2018) CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiol Biomarkers Prev 27:1364-1370
Supekar, Nitin T; Lakshminarayanan, Vani; Capicciotti, Chantelle J et al. (2018) Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide. Chembiochem 19:121-125
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Zhang, Mingfeng; Lykke-Andersen, Soren; Zhu, Bin et al. (2018) Characterising cis-regulatory variation in the transcriptome of histologically normal and tumour-derived pancreatic tissues. Gut 67:521-533
Kanamori, Karina S; de Oliveira, Guilherme C; Auxiliadora-Martins, Maria et al. (2018) Two Different Methods of Quantification of Oxidized Nicotinamide Adenine Dinucleotide (NAD+) and Reduced Nicotinamide Adenine Dinucleotide (NADH) Intracellular Levels: Enzymatic Coupled Cycling Assay and Ultra-performance Liquid Chromatography (UPLC)-Mass Bio Protoc 8:
Hu, Chunling; Hart, Steven N; Polley, Eric C et al. (2018) Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA 319:2401-2409
Orozco, Carlos A; Martinez-Bosch, Neus; Guerrero, Pedro E et al. (2018) Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc Natl Acad Sci U S A 115:E3769-E3778
Radecki Breitkopf, Carmen; Wolf, Susan M; Chaffee, Kari G et al. (2018) Attitudes Toward Return of Genetic Research Results to Relatives, Including After Death: Comparison of Cancer Probands, Blood Relatives, and Spouse/Partners. J Empir Res Hum Res Ethics 13:295-304

Showing the most recent 10 out of 336 publications